Unique ID issued by UMIN | UMIN000001406 |
---|---|
Receipt number | R000001710 |
Scientific Title | Pharmacokinetic Study of IDEC-C2B8 in Patients with Childhood-onset Refractory Nephrotic Syndrome |
Date of disclosure of the study information | 2008/10/02 |
Last modified on | 2014/06/02 19:13:09 |
Pharmacokinetic Study of IDEC-C2B8
in Patients with Childhood-onset Refractory Nephrotic Syndrome
Pharmacokinetic Study of IDEC-C2B8
(RCRNS02)
Pharmacokinetic Study of IDEC-C2B8
in Patients with Childhood-onset Refractory Nephrotic Syndrome
Pharmacokinetic Study of IDEC-C2B8
(RCRNS02)
Japan |
Childhood-onset Refractory Nephrotic Syndrome
Nephrology | Pediatrics |
Others
NO
To evaluate the pharmacokinetic profiles of IDEC-C2B8 in patients with childhood-onset refractory nephrotic syndrome.
Safety,Efficacy
Phase III
Investigation of pharmacokinetic profiles
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
IDEC-C2B8
2 | years-old | <= |
Not applicable |
Male and Female
1. Diagnosed as idiopathic nephrotic syndrome (INS) according to the ISKDC criteria
2. The first onset of INS is between 1 - 18 years of age, and 2 years of age or older at entry
3. Subjects meeting either one of the following criteria:
1) having relapsed within 85 days (during Day 1 to Day 85) after receiving "placebo" in the double blind study (a separate study with protocol # RCRNS-01)
2) having diagnosed as frequently relapsing and steroid-dependent INS (FR-SD INS) during the period of Day 86 though Day 365 after receiving the "placebo" in the double blind study (protocol # RCRNS-01)
3) with a history of IDEC-C2B8 treatment for INS in the year of 2007 or before
4. Diagnosed as steroid-sensitive relapse
5. CD20 positive B-cells >/= 5/mcL in the peripheral blood
6. Subjects can be hospitalized for treatments of study drug
7. Subjects have ability to provide written informed consent form. The written informed consent form of legal representative (i.e., a parent or a legal benefactor) is also required for subjects less than 20 years of age
1. History of inflammatory nephritis such as IgA nephritis
2. History of immunosuppressive treatment for INS other than cyclosporine A, tacrolimus, cyclophosphamide, mizoribine, azathioprine, mycophenolate mofetil and chlorambucil
3. History of serious infectious diseases such as pulmonary tuberculosis and deep-seated fungal diseases
4. Positive for HCV antibody, HBs antigen, HBc antibody and HIV antibody
5. Having received a live vaccine within 4 weeks prior to screening
6.Known hypertension which is uncontrollable with conventional anti-hypertensive
7. Deteriorated kidney function, e.g. estimated GFR<60mL/min./1.73m2
8. Deteriorated liver function, e.g., AST or ALT > 2.5 x upper limit of normal value
9. Presence or history of angina pectoris, cardiac failure, myocardial infarction and/or serious arrhythmia grade 4 in "Common Terminology Criteria for Adverse Events (ver. 3.0)"
10. Presence or history of auto-immune diseases such as Hashimoto disease (struma lymphomatosa), Crohn's disease, ulcerative colitis, rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, autoimmune hemolytic anemia, scleroderma or vascular purpura
11. Presence or history of cancer
12. History of organ transplantation
13. History of allergic reaction to methylprednisolone, acetaminophen and/or d-chlorpheniramine maleate
14. Presence of hematological disorder, e.g., WBC < 2,000/mcL, neutrophil < 1,500/mcL, PLT <50,000/mcL
15. History of receiving any kinds of monoclonal antibody therapy except for IDEC-C2B8
16. Having received any investigational agent within 6 months prior to enrollment, or participating other clinical studies
17. Pregnant subjects or subjects who do not agree with contraception during the study period (Negative HCG result is required at screening for female subjects after the first menstruation.)
18.Judged inappropriate for this study by the physicians
20
1st name | |
Middle name | |
Last name | Kazumoto Iijima |
Division of Child Health and Development
Department of Pediatrics
Kobe University Graduate School of medicine
Department of Pediatrics
5-1 Kusunoki-cho 7 chome
1st name | |
Middle name | |
Last name |
Kobe University Hospital
Research group of Childhood-onset Refractory Nephrotic Syndrome
rcrns@med.kobe-u.ac.jp
Research group of Childhood-onset Refractory Nephrotic Syndrome
Center for Clinical Trials, Japan Medical Association
NO
2008 | Year | 10 | Month | 02 | Day |
Unpublished
Completed
2008 | Year | 06 | Month | 05 | Day |
2008 | Year | 10 | Month | 01 | Day |
2011 | Year | 12 | Month | 01 | Day |
2013 | Year | 12 | Month | 27 | Day |
2008 | Year | 10 | Month | 01 | Day |
2014 | Year | 06 | Month | 02 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001710
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |